News & Events

Want to see what we’ve been up to? Check out our latest news, events and press releases.

Press Releases

Aitia and G3 Therapeutics Publish Results Identifying New Causal Biomarkers of Atherosclerotic Coronary Artery Disease (ASCAD), the Leading Cause of Morbidity and Mortality Worldwide

G3 Therapeutics, a life sciences company that leverages large-scale multi-omic biological big data to develop life-changing therapeutics and diagnostics, and Aitia, the leader in the application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced results of research that identified new causes of ASCAD.

read more

GNS Rebrands as Aitia to Focus on AI-Enabled Drug Discovery

GNS, the leader in the application of causal AI and “Digital Twins” to discover and develop new drugs, announced today its rebranding as Aitia (pronounced “ay-tee-ah”). Aitia, derived from the Greek word for causality, will focus on further leveraging its Gemini Digital Twins to discover the next generation of breakthrough drugs to improve outcomes for patients…

read more

GNS Announces Abstract and Oral Poster Presentation at CTAD & ASH, 2022 Annual Conferences

GNS, the leader in the application of Causal AI and simulation and “Digital Twins” to discover new drugs, today announced two abstracts and two oral poster presentations highlighting insight from the Gemini Digital Twin models in Alzheimer’s Disease and Multiple Myeloma will be included at the Clinical Trials on Alzheimer’s Disease conference (CTAD) in San Francisco and the American Society of Hematology (ASH) in New Orleans…

read more

GNS Appoints John Maraganore as Chair of the Board

GNS, the leader in the application of Causal AI and simulation and “Digital Twins” to discover new drugs, today announced that John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, has been appointed as the new GNS Chair of the Board…

read more